This week, the National Institute of Allergy and Infectious Diseases released a disappointing update from a Phase IIb proof-of-concept study for an investigational HIV vaccine made by Johnson & Johnson. The data from the “Imbokodo” clinical trial, conducted in sub-Saharan Africa, suggest that the HIV vaccine—with an efficacy of 25.2%—showed a lack of sufficient protection in women. Notably, the vaccine posed no safety concerns.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed